AGE-RELATED MACULAR DEGENERATION CURRENT INVESTIGATIONS AND TREATMENTS

agerelatedmaculardeg774enerationkapak

OTHER TREATMENT MODALITIES IN DRY AGE-RELATED MACULAR DEGENERATION

Emre Aydın1
Şaban Kılıç2

1Samsun University, Faculty of Medicine, Department of Ophthalmology, Samsun, Türkiye
2Samsun Training and Research Hospital, Department of Ophthalmology, Samsun, Türkiye

Aydın E, Kılıç Ş. Other Treatment Modalities in Dry Age-Related Macular Degenerati. In: Çıtırık M, Şekeryapan Gediz B, editors. Age-Related Macular Degeneration: Current Investigations and Treatments. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.111-121.

ABSTRACT

Research into the treatment of dry AMD continues intensively. Some promising therapeutic molecules have generated great excitement in early studies but have not shown significant results in clinical trials. Groundbreaking treatment options for dry AMD are Pegcetacoplan and avancincaptad pegol, which have been approved by the FDA. Although the decision to treat GA patients is complex and delicate, the approval of these two treatment options is considered a major advance in the field of ophthalmology. Finally, the FDA approval of PBM therapy has strengthened the hands of physicians in the treatment. The FDA approval of these treatments opens the door to new possibilities in the treatment of dry AMD, increases the hope of preserving vision, and has the potential to make a major difference in the lives of patients affected by this condition. In the future, better insights into the pathophysiology of dry AMD may broaden the horizons of potential therapeutic targets in the treatment of GA and intermediate AMD.

Keywords: Retinal drusen; Geographic atrophy; Retinal pigment epithelium; Choroidal neovascularization

Referanslar

  1. Anand David AV, Arulmoli R, Parasurman S. Overviews of biological importance of guercetin: a bioactive flavonoid . Pharmacogn Rev. 2016; 10:84-9. [Crossref]  [PubMed]  [PMC]
  2. Weng S, Mao L, Gong Y, Sun T, Gu Q. Role of guercetin in protecting ARPE19 cell against H202nduced injury via nuclear factor erythroid 2 like 2 pathway activation and endoplasmic reticulum stress inhibition. Mol Med Rep. 2017;16:3461-8. [Crossref]  [PubMed]
  3. Ramírez C, Cáceres-del-Carpio J, Chu J, et al. Brimonidine can prevent in vitro hydroquinone damage on retinal pigment epithelium cells and retinal Müller cells. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2016;32(2):102-8. [Crossref]  [PubMed]  [PMC]
  4. Ghosn C, Almazan A, Decker S, Burke JA. Brimonidine drug delivery system (Brimo DDS Generation 1) slows the growth of retinal pigment epithelial hypofluorescence following regional blue light irradiation in a nonhuman primate (NHP) model of geographic atrophy (GA). Investig Ophthalmol Vis Sci. 2017;58(8):1960-1960. [Link]
  5. Kuppermann BD, Patel SS, Boyer DS, et al. Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) Generation 1 in patients with geographic atrophy secondary to age-related macular degeneration Retina. 2021; 41:144-155. [Crossref]  [PubMed]
  6. Freeman WR, Bandello F, Souied EH, et al. Phase 2b study of brimonidine DDS: potential novel treatment for geographic atrophy. Investig Ophthalmol Vis Sci. 2019;60(9):971-971. [Link]
  7. Fuhrmann S, Grabosch K, Kirsch M, Hofmann H-D. Distribution of CNTF receptor alpha protein in the central nervous system of the chick embryo. J Comp Neurol. 2003;461(1):111-22. [Crossref]  [PubMed]
  8. Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Investig Ophthalmol Vis Sci. 2012;53(12):7484-91. [Crossref]  [PubMed]
  9. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Investig. 2006;116(2):378-85. [Crossref]  [PubMed]  [PMC]
  10. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99(18):11830 5. [Crossref]  [PubMed]  [PMC]
  11. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res. 2008;33(11):1011-3. [Crossref]  [PubMed]
  12. Rosenfeld PJ, Berger B, Reichel E, et al. A randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration. Ophthalmol Retina. 2018;2(10):1028-40. [Crossref]  [PubMed]
  13. Ding J-D, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes RC. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res. 2008;48(3):339-45. [Crossref]  [PubMed]  [PMC]
  14. Pfizer. A phase 2 multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of Rn6g (Pf-04382923). In: subjects with geographic atrophy secondary toage- related macular degeneration. clinicaltrials.gov; 2016. Accessed 4 Nov 2020. [Link]
  15. Parsons CG, Ruitenberg M, Freitag CE, Sroka-Saidi K,Russ H, Rammes G. MRZ-99030-a novel modulator of Aβ aggregation: I-mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). Neuropharma-cology. 2015;92:158-69. [Crossref]  [PubMed]
  16. Shenouda Girgis, Lawrence R Lee. Treatment of dry age-related macular degeneration: A review. Clin Exp Ophthalomol. 2023;51(8):835-852. [Crossref]  [PubMed]
  17. Mihai DM, Washington I. Vitamin A dimers trigger the protracted death of retinal pigment epithelium cells. Cell Death Dis. 2014;5(7):e1348. [Crossref]  [PubMed]  [PMC]
  18. Issa PC, Barnard AR, Washington I, MacLaren RE. C20-D3-Vitamin A (ALK-001) rescues the phenotype of an- Abca4−/mouse model of Stargardt disease. Investig Ophthalmol Vis Sci. 2014;55(13):5015. [Link]
  19. Saad L. A Phase 2/3 Multicenter, Randomized, Double-Masked, Parallel-group, Placebo-controlled Study to İnvestigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration. ClinicalTrials.gov identifier:NCT03845582. Updated February 16, 2022. [Link]
  20. Bavik C, Henry SH, Zhang Y, et al. Visual cycle modulation as an approach toward preservation of retinal integrity. PLoS One. 2015;10(5): e0124940. [Crossref]  [PubMed]  [PMC]
  21. Rosenfeld PJ, Dugel PU, Holz FG, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2018;125(10):1556-67. [Crossref]  [PubMed]
  22. Brown EE, Lewin AS, Ash JD. Mitochondria: Potential targets for protection in age-related macular degeneration. AdvExp Med Biol. 2018; 1074:11-7. [Crossref]  [PubMed]
  23. Cousins SW, Saloupis P, Brahmajoti MV, Mettu PS. Mitochondrial dysfunction in experimental mouse models of SubRPE deposit formation and reversal by the Mito-reparative drug MTP- 131. Investig Ophthalmol Vis Sci.2016;57(12):2126-2126. [Link]
  24. Retinal Physician-The ReCLAIM Phase 1 Clinical Trial of Elamipretide for Dry AMD. Retinal Physician. Accessed 23 June 2020. [Link]
  25. Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions. BioSpace. Accessed 22 Nov 2019. [Link]
  26. Quiroz-Mercado H. Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 - (Luminate®) in Diabetic Macular Edema. In: Presented at the: The Association for Research in Vision and Ophthalmology; April 2018; Honolulu, Hawaii. [Link]
  27. Yang P, Neal SE, Jaffe GJ. Luminate protects against hydroqui- none-induced injury in human RPE cells. Investig Ophthalmol Vis Sci. 2019;60(9):1944-1944. [Link]
  28. Choi EJ, Choi GW, Kim JH, et al. A novel Eye drop candidate for age-related macular degeneration treatment: studies on its pharmacokinetics and distribution in rats and rabbits. Molecules. 2020 Feb 4;25(3):663. [Crossref]  [PubMed]  [PMC]
  29. Booij JC, Baas DC, Beisekeeva J, Gorgels TGMF, Bergen AAB. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29(1):1-18. [Crossref]  [PubMed]
  30. Effects of hydralazine on ocular blood flow and laser-induced choroidal neovascularization. Accessed 11 June 2020. [Link]
  31. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of Drusen associated with glomerulonephritis: implications for the role of complement activation in Drusen biogenesis. Eye Lond Engl. 2001;15(Pt 3):390-5. [Crossref]  [PubMed]
  32. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102(20):7227-32. [Crossref]  [PubMed]  [PMC]
  33. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458-62. [Crossref]  [PubMed]  [PMC]
  34. Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration. BioSpace. Accessed 5 Nov 2020. [Link]
  35. Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017 Jun 21;9(395):eaaf1443. [Crossref]  [PubMed]
  36. Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666-77. [Crossref]  [PubMed]  [PMC]
  37. Yehoshua Z, de Garcia Filho CAA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693-701. [Crossref]  [PubMed]  [PMC]
  38. Zimura phase 2b trial results positive in geographic atrophy secondary to dry AMD. October 28, 2019. Accessed 3 Dec 2019. [Link]
  39. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age- related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020 Feb;127(2):186-195. [Crossref]  [PubMed]
  40. David S. Liao MD et al. Complement C3 İnhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020;127(2):186-195. [Crossref]  [PubMed]
  41. Chichagova V, Hallam D, Collin J, et al. Cellular regeneration strategies for macular degeneration: past, present and future. Eye (Lond) 2018;32:946-971. [Crossref]  [PubMed]  [PMC]
  42. Schwartz SD, Hubschman J-P, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet Lond Engl. 2012;379(9817):713-20. [Crossref]  [PubMed]
  43. Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age- related macular degeneration. Sci Transl Med. 2018 Apr 4;10(435):eaao4097. [Crossref]  [PubMed]
  44. Riemann CD, Banin E, Barak A, et al. Phase I/IIa clinical trial of human embryonic stem cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen) transplantation in advanced dry form age-related macular degeneration (AMD): interim results. Investig Ophthalmol Vis Sci. 2020;61(7):865-865. [Link]
  45. Jobling AI, Guymer RH, Vessey KA, et al. Nanosecond laser therapy reverses pathologic and molecular changes in age- related macular degeneration without retinal damage. FASEB J Off Publ Fed Am SocExp Biol. 2015;29(2):696-710. [Crossref]  [PubMed]
  46. Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold nano- second laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial. Ophthalmology. 2019;126(6):829-38. [Crossref]  [PubMed]
  47. Grossman N, Schneid N, Reuveni H, Halevy S, Lubart R.780 nm low power diode laser irradiation stimulates proliferation of keratinocyte cultures: involvement of reactive oxygen species. Lasers Surg Med. 1998;22(4):212-8. [Crossref]  [PubMed]
  48. Wong-Riley MTT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280(6):4761-71. [Crossref]  [PubMed]
  49. Eells JT, Wong-Riley MTT, VerHoeve J, et al. Mitochondrial signal transduction in accelerated wound and retinal healing by near infrared light therapy. Mitochondrion. 2004;4(5-6):559-67. [Crossref]  [PubMed]
  50. Gkotsi D, Begum R, Salt T, et al. Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP. Exp Eye Res. 2014;122:50-3. [Crossref]  [PubMed]
  51. Tang J, Du Y, Lee CA, Talahalli R, Eells JT, Kern TS. Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro. Investig Ophthalmol Vis Sci. 2013;54(5):3681-90. [Crossref]  [PubMed]  [PMC]
  52. Dang Y., Zhang C., Zhu Y. Stem cell therapies for age-related macular degeneration: the past, present, and future. Clinical Interventions in Aging. 2015;10:255-264. [Crossref]  [PubMed]  [PMC]
  53. Falkner-Radler C. I., Krebs I., Glittenberg C., et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. British Journal of Ophthalmology. 2011;95(3):370-375. [Crossref]  [PubMed]
  54. Cho M. S., Kim S. J., Ku S. Y., et al. Generation of retinal pigment epithelial cells from human embryonic stem cell-derived spherical neural masses. Stem Cell Research. 2012;9(2):101-109. [Crossref]  [PubMed]
  55. Kokkinaki M., Sahibzada N., Golestaneh N. Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE. Stem Cells. 2011;29(5):825-835. [Crossref]  [PubMed]  [PMC]
  56. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell- based therapies. Stem Cells. 2007;25:818-882. [Crossref]  [PubMed]
  57. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509-516. [Crossref]  [PubMed]
  58. Wei Xiang et al. PEDF protects retinal pigment epithelium from ferroptosis and ameliorates dry AMD-like pathology in a murine model. GeroScience. 2023;46(2):2697 2714. [Link] https://pubmed.ncbi.nlm.nih.gov/38153666 [Crossref]  [PubMed]  [PMC]
  59. Weiss JN, Levy S. Stem cell ophthalmology treatment study (SCOTS): bone marrow-derived stem cells in the treatment of age-related macular degeneration. Medicines (Basel). 2020;7(4):16. [Crossref]  [PubMed]  [PMC]
  60. Rencova E, Blaha M, Studnicka J, et al. Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis. J Ophthalmol 2015; 2015:359747. [Crossref]  [PubMed]  [PMC]
  61. Pierson RF, Orr S, Bogert J, et al. Health-related quality of life in patients with moderate to advanced dry age-related macular degeneration: results from a phase 1/2a clinical trial of Cnto 2476. Value Health 2016;19:A127. [Crossref]
  62. Qinyi Hui et al. Isorhamnetin suppresses the epithelial-mesenchymal transition of the retinal pigment epithelium both in vivo and in vitro through Nrf2-dependent AKT/ GSK-3ß pathway. Experimental Eye Research. 2024 Mar:240:109823. [Crossref]  [PubMed]
  63. Berdugo et al. The antidiabetic drug glibenclamide exerts direct retinal neuroprotection. Transl Res. 2021; 229:83-99. [Crossref]  [PubMed]
  64. Luteoloside mitigates premature age-related macular degeneration by suppressing p53-p21-Rb1 axis: Insights from transcriptomic analysis, serum metabolomics and gut microbiota analysis. Journal of Pharmaceutical and Biomedical Analysis. Volume 248, 15 September 2024, 116296. [Crossref]  [PubMed]
  65. Sonali Nashine et al. Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage. Cell Death Dis. 2017 Jul 20;8(7):e2951. [Crossref]  [PubMed]  [PMC]
  66. Kang et al. Exosomal proteins in the agueous humor as novel biomarkers in patients with neovascular age-related macular degeneration. 2014. J.Proteomics 75, 3574-3584. [PubMed]
  67. Shakeel L, Khan A,Akilimali A.Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy. Ann Med Surg (Lond). 2024 Apr 3;86(5):2413. [Crossref]  [PubMed]  [PMC]
  68. Nadeem A. et al. Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. Ann Med Surg (Lond).2023 Nov 1;85(12):6067-6077. [Crossref]  [PubMed]  [PMC]
  69. Burton B. et al. A Response to: Letter to the Editör Regarding ''LİGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration''. Ophthalmol Ther. 2024;13(4):1055-1060. [Crossref]  [PubMed]  [PMC]